Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesTargeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsPredictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing SpondylitisConsistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers.Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA sComparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritisEmerging drugs for axial spondyloarthritis including ankylosing spondylitis.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
P2860
Q26778600-E4CE8E0A-8551-4C18-A851-7AAE13609743Q28073436-18DEB68E-7417-411E-8A1F-CC25AE3E8493Q28546596-9E7D000B-A71D-4C77-9568-20379D8780ADQ30936806-B3514413-3CAC-4622-B8D2-606B681FDB58Q34208252-E6292B89-93F8-4884-9781-ACA804D08602Q36550842-4A1C0716-1344-4FF3-B905-7A8C3E33BFA3Q37151351-1FFFC435-94C5-4F65-ACC7-8E4EAEFEC17EQ38068578-D4459D52-CC13-4ECA-B43E-31A4816EA942Q38238931-C388DBBF-6B98-40BD-A74B-F4A26DC01AC3Q38264660-60670F99-A624-4BB7-A498-68A4E4217126Q38673326-093B347E-DB8A-4E6A-A600-A3DF17B90D79Q38755133-49C60133-DF5A-4E52-A818-626823FD4BB5Q39712047-96529F1F-E849-4552-91D0-D4F533DCD150Q51036235-15C71A60-A84A-476B-9C30-7ED144D5D0F5Q51714525-0B19DC74-A073-4562-9ACA-EB288C0BCF4A
P2860
Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Age at treatment predicts reas ...... m the BIOBADASER 2.0 registry.
@ast
Age at treatment predicts reas ...... m the BIOBADASER 2.0 registry.
@en
type
label
Age at treatment predicts reas ...... m the BIOBADASER 2.0 registry.
@ast
Age at treatment predicts reas ...... m the BIOBADASER 2.0 registry.
@en
prefLabel
Age at treatment predicts reas ...... m the BIOBADASER 2.0 registry.
@ast
Age at treatment predicts reas ...... m the BIOBADASER 2.0 registry.
@en
P2093
P50
P356
P1433
P1476
Age at treatment predicts reas ...... om the BIOBADASER 2.0 registry
@en
P2093
Andrés Ponce
BIOBADASER 2.0 Study Group
Eva Tomero
Juan J Gómez-Reino
Noemí Busquets
P304
P356
10.1093/RHEUMATOLOGY/KER281
P577
2011-08-19T00:00:00Z